Knowthestock.com
CORT - Corcept Therapeutics Inc

Hold

Strong Growth and Improving
WeakStrong
WeakStrong

83%

based on last 5 year data.
Income Statement is STRONG
Revenue Growth is 30.93%
Operating Income Growth is -9.07%
Net Income Growth is 13.06%
Earnings Per Share (EPS) Growth is 8.49%
Net Margin is 19.33%
Balance Sheet is STRONG
Current Asset to Current Liability Ratio is 3.07
Debt Ratio is 0.19
Current Debt to Net Income Ratio is 0.0
Total Debt to Total Assets Ratio is 0.0
Cash Flow is MODERATE
Cash from Operations Growth is 43.74%
Capital Expenditure is Low
Net Increase in Cash is Negative
Long Term Score Trend is POSITIVE
Investment Risk is High
based on last 4 quarter data.
Better viewed in landscape mode.
Unless specified, all values are in USD Millions. Data extracted from SEC Filing and are subject to processing and input errors.
Corcept Therapeutics Inc (CORT) - http://www.corcept.com/
leading the field in the discovery of drugs that modulate the effects of cortisol the adverse effects of excess cortisol have been corcept’s focus since the company’s inception. abnormal levels and release of cortisol play a role in a variety of metabolic, oncological, and psychiatric diseases, and we are currently studying a new generation of compounds that may mitigate the effects of excess cortisol. in addition to our work with mifepristone, we have developed over 300 proprietary molecules, advancing the most promising of these to the clinic to see if they can mitigate the effects of excess cortisol and the serious, sometimes life-threatening conditions that may result. all of these compounds competitively block the glucocorticoid receptor (gr), but not the progesterone receptor. scientific literature suggests that competitive gr antagonism may have a role in treating many conditions, including post-traumatic stress disorder, mild cognitive impairment, alzheimer’s disease, alcoholis
Exchange - NASDAQ
Industry - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Sector - Professional, Scientific, and Technical Services
CEO - Joseph Belanoff
Employees - 309
    Close

    Login/Register

    Home


Cookie Policy
Disclaimer - Investment in securities involves substantial risk and could result in significant loss. It is not suitable for every investor. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. We may own some of the securities mentioned in this website.
Know the Stock © 2025 and future.